Dear Friends, I’m sure you agree—2020 was a year like no other. Yet, despite the challenges presented by COVID-19, the Lupus Research Alliance (LRA) managed – thanks to loyal supporters like you – to find creative solutions to keep the lupus community and our pioneering research where they belong: front and center I’m proud to […] READ MORE
February 22, 2021 In a recent study published in Arthritis & Rheumatology, LRA-funded researcher Dr. Xian Zhang found that a low dose of the chemotherapy drug topotecan reduced the inflammation and kidney damage of lupus nephritis in mice with lupus. Topotecan was as effective as high doses of cyclophosphamide, another chemotherapy that’s currently used to […] READ MORE
Your voices will be heard as loud and clear as ever, albeit virtually! Join us Monday, March 15 for our Advocate for Lupus Research meeting presented by PA Fund for Patient Advocacy at the LRA. Click here to join the virtual event. Hear from DC experts and experienced lupus advocates on how to advocate effectively and what we need Congress to […] READ MORE
While the pandemic made it impossible for the LRA to hold in person fundraising events, we still achieved great success thanks to the determination of our supporters to fund crucial lupus research. Likewise, our “virtual gala” – bolstered by superstars like Lady Gaga and Selena Gomez – raised an astounding $3.3 million and was attended […] READ MORE
February 10, 2021 The worldwide lupus community lost a brilliant researcher and a passionate champion with the recent passing of rheumatologist Marc Chevrier, MD, PhD, FACR. A larger-than-life personality with a huge heart to match, Dr. Chevrier was a devoted friend to hundreds of people with lupus and those who care for them. Perhaps most […] READ MORE
February 4, 2021 “Imagine that your house is on fire and someone inside started it – that’s lupus,” says Dr. Giya Harry. “Steroids are the fire hoses we’re using to put the fire out fast! Other medications are the tools to rebuild the house and protect it from catching fire again.” Using concrete comparisons like […] READ MORE
January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […] READ MORE
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] READ MORE
January 14, 2020 Dear Friends, Happy New Year! On behalf of all of us at the Lupus Research Alliance (LRA), thank you so much for your kindness and generosity in 2020 and prior years. 2021 starts off with some exciting milestones for the lupus community including a new treatment for lupus nephritis. But Recently, our […] READ MORE
January 14, 2021 LRA’s President and CEO Kenneth Farber taped this video series – Vaccines and Lupus: What to Know Amid COVID-19 – to explain what vaccines do, how the new COVID-19 vaccine technologies work, and what the LRA is doing to address questions on the safety of these new vaccines for people with lupus. […] READ MORE
December 28, 2020 After much back and forth, last week the U.S. Congress passed the year-end spending deal, called the Omnibus, and President Trump signed it into law Sunday night. It’s because of your efforts during the LRA’s Virtual Hill Day in March that the need to fund research for lupus and other medical conditions […] READ MORE
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] READ MORE
